Skip to main content

Search

Reset all filters
329 Result(s)
Sort by

Combination Therapy

Combination Therapy

It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
The big, the bold, and the few

The big, the bold, and the few

In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Newsbits

Newsbits

Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Bees and biodiversity

Bees and biodiversity

At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
China pioneers biosecurity report against ASF

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Cancer's Big 4

Cancer's Big 4

We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
sustainably fighting rabies info hub

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.